(Q26991637)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

review article

3 references

1 September 2020

28 January 2021

Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

AKT serine/threonine kinase 1

16 February 2020

main subject

1 reference

diffuse large B-cell lymphoma

1 September 2020

2 references

1 September 2020

18 September 2020

Serine/threonine-protein kinase TOR

1 reference

28 January 2021

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

3

Piotr Smolewski

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Agata Majchrzak

series ordinal

1

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

1 reference

11 September 2014

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 September 2020

28 January 2021

4 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 September 2020

28 January 2021

19

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

14304-14315

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

9

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

16 February 2020

copyright license

3 references

1 September 2020

18 September 2020

28 January 2021

0 references

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Novel therapeutic targets in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Class I PI3K in oncogenic cellular transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

PI3K in lymphocyte development, differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

p87 and p101 subunits are distinct regulators determining class IB phosphoinositide 3-kinase (PI3K) specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

mTOR inhibitors in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Two birds with one stone: dual p110δ and p110γ inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES190914304

Diffuse large B-cell lymphoma: current strategies and future directions

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/25215588

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25215588

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25215588

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3390/MOLECULES190914304

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25215588%20AND%20SRC:MED&resulttype=core&format=json